Evaluating Normal Values Methods for Longitudinal Data Defining Expected Quality of Life After Prostate Cancer Treatment Jeff Slezak, MS.

Slides:



Advertisements
Similar presentations
Progress Against Prostate Cancer. 1970–1979 Progress Against Prostate Cancer 1970–1979 Early 1970s: Radioactive ''seeds'' proven effective for prostate.
Advertisements

ASSESSING RESPONSIVENESS OF HEALTH MEASUREMENTS. Link validity & reliability testing to purpose of the measure Some examples: In a diagnostic instrument,
PROSTATE CANCER Dr Samad Zare Assistant Proffesor of Urology Shaheed Sadoughi University of Medical Sciences.
Survey among men who have had Prostate Cancer Media Briefing: 30 th September 2011.
IDEA Student Ratings of Instruction Update Carrie Ahern and Lynette Molstad Selected slides reproduced with permission of Dr. Amy Gross from The IDEA Center.
Clinically localized prostate cancer: Prostatectomy David D. Thiel, MD Mayo Clinic Florida Department of Urology.
Carcinoma of the Prostate By: Ishan Parikh. Background on Cancer  Oldest information dates back to 3000 BC, Egyptian textbook on trauma surgery – “There.
Analysis of Prostate Cancer Prevention Behavior in Florida Utilizing The 2002 BRFSS Data Yussif Dokurugu MPH Candidate April 9, 2004.
AM Report 9/11/09 Prostate Cancer Julia Rauch. Disease Burden ~220,000 men were diagnosed with prostate cancer in 2007 ~1/6 men will receive the disagnosis.
Meta-Analysis of PSA Growth Lurdes Y.T. Inoue, Ph.D. Ruth Etzioni, Ph.D. Elizabeth Slate, Ph.D. Christopher Morrel, Ph.D.
Surgery v Radiation in Prostate Cancer Prasanna Sooriakumaran MD PhD & Peter Wiklund MD PhD.
Ihor S. Sawczuk, M.D. PROFESSOR & CHAIRMAN UROLOGY TOURO UNIVERSITY COLLEGE OF MEDICINE ADJUNCT PROFESSOR OF UROLOGY COLLEGE OF PHYSICIANS & SURGEONS.
NEW OPTIONS IN PROSTATE CANCER TREATMENT Presented by Triangle Urology Associates, P.A.
Salutogeneses - perception of life quality L Jakobsson Dr med sci, RNT Kristianstad University Sweden.
Dobson DaVanzo & Associates, LLC Vienna, VA Prostate Cancer Patients Report on Benefits of Proton Therapy: Follow- on.
Tang G et al. Proc SABCS 2010;Abstract S4-9.
Surrogate End point for Prostate Cancer- Specific Mortality After RP or EBRT A D’Amico J Nat Ca Inst 95,
Silent Voice Survey A survey of prostate cancer patients in Europe OVERVIEW OF RESULTS.
Dan Spratt, MD Department of Radiation Oncology Neuroendocrine Prostate Cancer: FDG-PET and Targeted Molecular Imaging.
Prostate Cancer: A Case for Active Surveillance Philip Kantoff MD Dana-Farber Cancer Institute Professor of Medicine Harvard Medical School.
Some Current Issues in the Management of Prostate Cancer Suman Chatterjee MD.
Genomic Health, Inc. Yuko Soneoka, Ph.D., J.D. Senior Corporate Counsel, IP Director of Intellectual Property January 31, 2013.
SEER Provided Data Mohammad Afnan Baqai 12/3/2009.
Prostate Cancer Coalition of NC A statewide collaborative effort by concerned organizations and individuals to support awareness, early detection, and.
Prostate Cancer: Treatment choices Prostate Cancer: Treatment choices Winston W Tan MD FACP Winston W Tan MD FACP Senior Consultant Senior Consultant Genitourinary.
Prostate Cancer Management: A Guide for Patients and Caregivers
FREEDOM FROM PROGRESSION FOR PATIENTS RECEIVING I 125 VERSUS Pd 103 FOR PROSTATE BRACHYTHERAPY Jane Cho, Carol Morgenstern, Barbara Napolitano, Lee Richstone,
Assessing Responsiveness of Health Measurements Ian McDowell, INTA, Santiago, March 20, 2001.
Quality of Life and Functional Results Following Pelvic Exenteration Erin Kennedy September 19, 2015.
The Role of Cyberknife Stereotactic Body Radiation Therapy in the Treatment of Localized Prostate Cancer David M. Spellberg M.D., FACS Naples Urology Associates,
Carcinoma of the prostate. INTRODUCTION Prostate cancer is the most common cancer diagnosed and is the second leading cause of cancer death in men in.
Quality of Life after Prostate Cancer Treatment: Trajectories of Recovery using Piecewise Latent Growth Curve Analyses Michael A. Diefenbach, Ph.D., Icahn.
1 RTOG 1115 Health Related Quality of Life and Comparative Effectiveness Deborah Watkins Bruner, RN, PhD, FAAN.
IMPACT OF STAGE MIGRATION ON NODE POSITIVE PROSTATE CANCER RATE AND FEATURES: A 20-YEAR, SINGLE INSTITUTION ANALYSIS IN MEN TREATED WITH EXTENDED PELVIC.
Global predictors of regression fidelity A single number to characterize the overall quality of the surrogate. Equivalence measures –Coefficient of multiple.
ALI ABBAS BIO 1301 PROSTATE CANCER. QUICK FACTS ABOUT PROSTATE CANCER 1.Prostate Cancer is the most common type of cancer among men in the United States.
National Cancer Institute U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health Post-Katrina Population Estimates Dave Stinchcomb.
DEMONSTRATION OF USING SPSS Logistic Regression Models for Prediction 2016/11/71.
Second Preventing Overdiagnosis Conference September 15-17, Oxford UK
Kelci J. Miclaus, PhD Advanced Analytics R&D Manager JMP Life Sciences
TEXILA AMERICAN UNIVERSITY
Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH): More Than Treating Symptoms?  Mark J. Speakman  European Urology Supplements 
PHEN Clinical Trials Rally
Your Symptoms Matter – Prostate Cancer
Creating the perfect text…
Factors Influencing Prostate Cancer Treatment Decisions for African American and White Men: Prostate Cancer Follow Back Study Keith Elder, MPA,MPH, PhD.
Prognosis of younger patients in non-small cell lung cancer
Sarah Leary, MD MS CBTTC 5/25/2016
PHQ2 Screening Negative PHQ2 Screening Positive
The valuation of disease-specific questionnaires for QALY analysis
Prostate Cancer: Highlights from 2006
Progressive Multiple Sclerosis and incontinence:
Apollo Gleneagles Hospitals,
Figure 3 Semantic model of the active surveillance (AS) timeline
Volume 71, Issue 5, Pages (May 2017)
Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH): More Than Treating Symptoms?  Mark J. Speakman  European Urology Supplements 
Evaluation and Medical Management of Benign Prostatic Hyperplasia
Volume 62, Issue 1, Pages (July 2012)
Volume 73, Issue 2, Pages (February 2018)
Might Men Diagnosed with Metastatic Prostate Cancer Benefit from Definitive Treatment of the Primary Tumor? A SEER-Based Study  Stephen H. Culp, Paul.
Dr. Nikki Cotterill ICS Travel Award and MS Society Junior Fellowship
2018 Postgraduate Research Symposium: Exploring opportunities
CAASPP Results 2015 to 2016 Santa Clara Assessment and Accountability Network May 26, 2017 Eric E, Zilbert Administrator, Psychometrics, Evaluation.
The Research Question 1) What is the contemporary prevalence of Active Surveillance (AS) adoption among men newly diagnosed with low-risk localized prostate.
Sixteen-Year Longitudinal Changes in Serum Prostate-Specific Antigen Levels: The Olmsted County Study  Steven J. Jacobsen, MD, PhD, Debra J. Jacobson,
Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia (LUTS/BPH): More Than Treating Symptoms?  Mark J. Speakman  European Urology Supplements 
Technical Innovations and Patient Support in Radiation Oncology
NAACCR/IACR Annual Conference, June 2019
Machine learning analysis for predicting survival in stage III non-small cell lung cancer patients receiving definitive chemotherapy and proton radiation.
Public Health Implications
Presentation transcript:

Evaluating Normal Values Methods for Longitudinal Data Defining Expected Quality of Life After Prostate Cancer Treatment Jeff Slezak, MS July 30, 2018 Goals Clinical: Provide personalized “normal values” for each patient for up to two years after treatment Better inform patients on treatment options Surgery, Radiation, Hormonal Therapy, Watchful Waiting, and combinations Set expectations and monitor progress; may be useful for both patients and providers Statistical: Determine the best methods for estimating percentiles for longitudinal, repeated-measures data Department of Research and Evaluation

Patient-reported Quality of Life Data 5727 men were mailed surveys at diagnosis and up to 2 years after treatment, with about 7700 completed responses Five domains Sexual function, Bowel function, Hormonal, Urinary continence, Urinary bother or irritation Each domain is based on several questions, standardized to a scale of 0 (worst) to 100 (best). Patient demographics Tumor characteristics (stage, grade, PSA, etc.) Treatments received

Normal Values Methods Methods Evaluated Linear regression with parametric z-score percentile estimation (O’Brien & Dyck) Quantile Regression Baysian estimation, estimating percentiles from posterior distribution Baysian quantile regression With and without adjustment for repeated measures The same predictors were used in all models 10-fold cross validation was used to assess model calibration

Comparing Percentile Estimates Example: Estimated percentiles of QOL score over time for 50 year-old man with good function before electing surgery. Quantile regression Parametric z-score Baysian Gray includes estimated 25th to 75th percentiles Red extends to 10th percentile, green to 90th percentile

Conclusions No method was clearly superior Parametric methods using linear regression and z-score percentile estimation, incorporating adjustment for repeated measures generally demonstrated the best overall calibration. Quantile regression notably underperformed in the case of strong ceiling effects (>25% of responses at top score) The impact of adjusting for repeated measures is small, but it does slightly improve percentile estimation Thanks to my collaborators, Drs. Steven Jacobsen, Gary Chein, and Stephanie Reading.